Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
PeDRA 2026: Nemolizumab Phase II Data Show Long — Term Symptom Relief for Children Aged 2 to 11 Years With Moderate — to — Severe Atopic Dermatitis
For best results when printing this announcement, please click on link below: PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderat